NAP1L4 in hepatocellular carcinoma progression and treatment from gene expression to clinical impact
SRGs, particularly NAP1L4, play critical roles in HCC progression. High NAP1L4 expression associates with poor prognosis, tumor microenvironment remodeling, and altered drug sensitivity. These findings support SRGs as potential prognostic biomarkers and therapeutic targets to enhance HCC treatment efficacy.
Authors
- Guang Chen (ORCID: https://orcid.org/0009-0007-9576-567X)
- Hang Yin (ORCID: https://orcid.org/0000-0002-0260-9130)
- Yuyao Li (ORCID: https://orcid.org/0000-0002-4057-6704)
- Zulong Xie
- Run-Min Yao
- Jiaojiao Shen (ORCID: https://orcid.org/0000-0002-4219-0936)
- Yufeng Gao (ORCID: https://orcid.org/0000-0003-1822-8161)
- Kexing Han
- Lulu Kong
- Junjie Lin (ORCID: https://orcid.org/0000-0003-3351-8482)
- Qingling Wang (ORCID: https://orcid.org/0000-0002-0793-5808)
- Meihui Liu (ORCID: https://orcid.org/0000-0002-4726-8851)
- Honghai Xu
Institutions
- Bengbu Medical College (CN)
- Xuzhou Medical College (CN)
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1007/s12672-025-04016-7
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00